Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05092269 · ClinicalTrials.gov registry record · Phase 3
A Long-term Extension Study of Ustekinumab in Pediatric Participants
A Phase 3 study of Crohn Disease and Colitis, Ulcerative, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
- 20
- Study locations
NCT05092269 is a Phase 3 study of Crohn Disease and Colitis, Ulcerative that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 159 participants, below the 203-participant average among 71 other Crohn Disease trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05092269, a Phase 3 study of Crohn Disease and Colitis, Ulcerative, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Conditions Studied
Interventions
- DRUG Ustekinumab
Study Locations (20)
Other
- STAT Research S A - Buenos Aires
- Hospital de Ninos de Cordoba - Córdoba
- Centro de Investigaciones Medicas Tucuman - San Miguel de Tucumán
- Huderf - Brussels
- Cliniques Universitaires Saint Luc - Brussels
- UZ Gent - Ghent
- UZ Brussel - Jette
- Uz Gasthuisberg - Leuven
- Hôpital Necker - Paris
- Universitaetsklinikum der RWTH Aachen - Aachen
- Charite Universitatsmedizin Berlin Campus Virchow Klinikum - Berlin
- Semmelweis Egyetem - Budapest
- Debreceni Egyetem Klinikai Kozpont - Debrecen
- Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz - Miskolc
- Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz - Nyíregyháza
- Szegedi Tudomanyegyetem - Szeged
Georgia
- Children's Center For Digestive Healthcare, Llc - Atlanta
New York
- Mount Sinai - New York
North Carolina
- Levine Childrens at Atrium Health - Charlotte
Virginia
- Pediatric Specialists Of Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2028-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05092269
The ClinicalTrials.gov registry entry for NCT05092269 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 71 other Crohn Disease trials with a reported enrollment target (22% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which Ustekinumab is the first listed.
NCT05092269 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT05092269 about?
NCT05092269 is a clinical study titled "A Long-term Extension Study of Ustekinumab in Pediatric Participants". The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
What is the current status of trial NCT05092269?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2021-10-18. Estimated completion is 2028-03-15.
What conditions does trial NCT05092269 study?
This clinical trial studies the following conditions: Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic.
What interventions are being tested in trial NCT05092269?
The interventions under investigation include: Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT05092269?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05092269 being conducted?
This trial has 20 study locations across Georgia, New York, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RECRUITING · Phase 3
-
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
COMPLETED · Phase 3
-
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
COMPLETED · Phase 3
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.